Records containing: Waldenstrom Macroglobulinemia

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-01-28
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib
CLINICAL_TRIALS study record update · 2026-01-27
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
CLINICAL_TRIALS study record update · 2026-01-02
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-12-10
A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
CLINICAL_TRIALS study record update · 2025-12-05
Efficacy of First Line Bortezomib, Rituximab, Ibrutinib (B-RI) for Patients With Treatment Naive Waldenström's Macroglobulinemia
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2025-12-05
Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG
CLINICAL_TRIALS study record update · 2025-11-28
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-11-28
A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-11-26
Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-11-26
Open Label Phase 2 Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia. A FILO Study
CLINICAL_TRIALS study record update · 2025-11-18
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
CLINICAL_TRIALS study record update · 2025-11-17
A Phase II Study of Time-limited Combination of Pirtobrutinib, Venetoclax, and Rituximab in Treatment Naïve Patients With Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) (PRoVen)
CLINICAL_TRIALS study record update · 2025-09-18
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-09-10
A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies
CLINICAL_TRIALS study record update · 2025-09-09
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-09-08
A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies
CLINICAL_TRIALS study record update · 2025-08-24
A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies
CLINICAL_TRIALS study record update · 2025-08-19
A Phase Ib /II Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)
CLINICAL_TRIALS study record update · 2025-08-07
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Lymphomas
CLINICAL_TRIALS study record update · 2025-06-27
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
CLINICAL_TRIALS study record update · 2025-05-29
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-05-23
A Phase II Study Evaluating Loncastuximab Tesirine in Patients With Previously Treated Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-05-11
A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström Macroglobulinemia
CLINICAL_TRIALS study record update · 2025-04-20
Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy
CLINICAL_TRIALS study record update · 2025-04-16
A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia